Mylan/Biovail verapamil
Executive Summary
Under a co-marketing agreement, Mylan and Biovail will bring a generic version of Schein/Elan's calcium channel blocker Verelan to the market earlier than anticipated, the companies announce May 19. Toronto-based Biovail was the first to file an ANDA for a generic version of the antihypertensive, and Mylan has received FDA approval to manufacture extended-release verapamil capsules in 120 mg, 180 mg and 240 mg strengths. Schein also announced that it would be marketing a generic sustained-release verapamil under a licensing agreement with Elan